We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Immunome Inc | NASDAQ:IMNM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -0.50% | 11.97 | 11.99 | 13.09 | 12.51 | 11.91 | 12.20 | 1,111,052 | 01:00:00 |
| | | | | S-ii | | | |
| | | | | S-1 | | | |
| | | | | S-4 | | | |
| | | | | S-6 | | | |
| | | | | S-8 | | | |
| | | | | S-10 | | | |
| CAPITALIZATION | | | | | S-11 | | |
| DILUTION | | | | | S-13 | | |
| | | | | S-15 | | | |
| UNDERWRITING | | | | | S-19 | | |
| | | | | S-30 | | | |
| EXPERTS | | | | | S-30 | | |
| | | | | S-30 | | | |
| | | | | S-30 | | |
| | | | | ii | | | |
| | | | | 1 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 12 | | | |
| | | | | 19 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 27 | | | |
| EXPERTS | | | | | 28 | | |
| | | | | 29 | | | |
| | | | | 30 | | |
| | |
As of September 30, 2023
|
| |||||||||||||||
| | |
Actual
|
| |
Pro forma(1)
|
| |
Pro forma
as adjusted |
| |||||||||
| | |
(In thousands, except share and per share data)
|
| |||||||||||||||
Cash and cash equivalents
|
| | | $ | 90,641(2) | | | | | $ | 139,384 | | | | | $ | | | |
Stockholders’ equity: | | | | | | | | | | | | | | | | | | | |
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, actual, pro forma and pro forma as adjusted; 12,202,516 shares issued and outstanding, actual; 45,027,683 shares issued and outstanding, pro forma; shares issued and outstanding, pro forma as adjusted
|
| | | | 1 | | | | | | 5 | | | | | | | | |
Additional paid-in capital
|
| | | | 136,248 | | | | | | 364,838 | | | | | | | | |
Accumulated deficit
|
| | | | (130,173) | | | | | | (251,552) | | | | | | | | |
Total stockholders’ equity
|
| | | | 6,076 | | | | | | 113,291 | | | | | | | | |
Total capitalization
|
| | | $ | 6,076 | | | | | $ | 113,291 | | | | | $ | | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Historical net tangible book value per share as of September 30, 2023
|
| | | $ | 0.50 | | | | | | | | |
|
Pro forma net tangible book value per share as of September 30, 2023
|
| | | $ | 2.52 | | | | | | | | |
|
Increase in pro forma net tangible book value per share attributable to new investors purchasing shares in this offering
|
| | | | | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share after giving effect to this
offering |
| | | | | | | | | $ | | | |
|
Dilution in net tangible book value per share to investors purchasing shares in this
offering |
| | | | | | | | | $ | | |
Name
|
| |
Number of
shares |
|
J.P. Morgan Securities LLC
|
| |
|
|
Cowen and Company, LLC
|
| | | |
Leerink Partners LLC
|
| | | |
Guggenheim Securities, LLC
|
| | | |
Wedbush Securities Inc.
|
| | | |
Total
|
| | | |
| | |
Without
option to purchase additional shares exercise |
| |
With full
option to purchase additional shares exercise |
| ||||||
Per Share
|
| | | $ | | | | | $ | | | ||
Total
|
| | | $ | | | | | $ | | | |
| Section 96(1) (a) | | | the offer, transfer, sale, renunciation or delivery is to: | |
| | | | (i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent; | |
| | | | (ii) the South African Public Investment Corporation; | |
| | | | (iii) persons or entities regulated by the Reserve Bank of South Africa; | |
| | | | (iv) authorised financial service providers under South African law; | |
| | | | (v) financial institutions recognised as such under South African law; | |
| | | | (vi) a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund, or | |
| | | | as manager for a collective investment scheme (in each case duly registered as such under South African law); or | |
| | | | (vii) any combination of the person in (i) to (vi); or | |
| Section 96(1) (b) | | | the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. | |
| | | | | ii | | | |
| | | | | 1 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 12 | | | |
| | | | | 19 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 29 | | | |
| | | | | 30 | | |
1 Year Immunome Chart |
1 Month Immunome Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions